Cencora (NYSE:COR) Announces Quarterly Earnings Results

Cencora (NYSE:COR) announced its quarterly earnings data on Wednesday. The company reported $4.66 EPS for the quarter, beating analysts’ consensus estimates of $4.58 by $0.08, FiscalAI reports. The firm had revenue of $88.35 billion for the quarter, compared to analyst estimates of $87.95 billion. Cencora had a return on equity of 125.45% and a net margin of 0.79%. The business’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same period last year, the company earned $3.84 EPS.

Here are the key takeaways from Cencora’s conference call:

• Cencora reported fiscal 2026 adjusted operating income growth of 14% and adjusted diluted EPS of $17.97, up 12%. Adjusted free cash flow was $3.8 billion, and the company announced a 10% increase to its quarterly dividend.
• The company is consolidating specialty capabilities into a new segment, targeting long-term operating income growth in the mid-teens; its fiscal 2027 segment outlook is 18%–21%, including the OneOncology acquisition contribution. Cencora expects specialty distribution revenue to reach approximately $100 billion in fiscal 2027.
• Fiscal 2027 adjusted EPS guidance is $19.40–$19.75, representing 8%–10% growth, or 10%–12% excluding the assumed MWI-Covetrus merger impact. Management projects operating income growth of 8.5%–11% excluding businesses in Other, ahead of its long-term targets.
• Reported fiscal 2027 operating income growth guidance is 4%–6%, with businesses in Other expected to reduce growth by about five percentage points; the Pharmaceutical Distribution and Services segment is forecast to grow operating income just 2%–4%, partly due to a customer volume shift and foreign exchange. Adjusted free cash flow is expected to decline to approximately $3.5 billion from $3.8 billion.

Cencora Trading Up 3.5%

Shares of Cencora stock traded up $11.88 on Wednesday, hitting $352.38. 1,746,557 shares of the company’s stock traded hands, compared to its average volume of 1,462,372. The firm’s 50-day moving average price is $324.08 and its two-hundred day moving average price is $317.45. The company has a debt-to-equity ratio of 3.53, a current ratio of 0.93 and a quick ratio of 0.58. The stock has a market capitalization of $67.24 billion, a PE ratio of 26.23, a price-to-earnings-growth ratio of 1.73 and a beta of 0.58. Cencora has a one year low of $244.82 and a one year high of $377.54.

Analyst Ratings Changes

Several brokerages have recently issued reports on COR. Weiss Ratings raised Cencora from a “buy (b-)” rating to a “buy (b)” rating in a research note on Tuesday, October 6th. JPMorgan Chase & Co. lifted their price objective on Cencora from $382.00 to $390.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Wall Street Zen raised Cencora from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Citigroup restated a “buy” rating on shares of Cencora in a research report on Thursday, August 6th. Finally, Wells Fargo & Company raised their target price on shares of Cencora from $331.00 to $395.00 and gave the company an “overweight” rating in a research note on Tuesday, August 11th. Fourteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, Cencora presently has an average rating of “Moderate Buy” and a consensus price target of $368.38.

More Cencora News

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Cencora reported adjusted Q4 EPS of $4.66, topping analyst estimates of about $4.58, while revenue of $88.4 billion also exceeded expectations. Revenue rose 5.5% year over year, and EPS increased from $3.84 a year earlier. The company also recorded its fifth consecutive earnings beat, according to the report. Article: Cencora Surpasses Q4 Earnings and Revenue Estimates
• Positive Sentiment: Cencora raised its dividend, adding a shareholder-return positive alongside the earnings beat. The dividend increase amount was not provided in the article summary. Article: Cencora Q4 2026 Earnings: Fifth Straight Beat, Dividend Raised
• Neutral Sentiment: The company is realigning its organizational and reporting structure to strengthen execution and improve visibility. The strategic change may support focus over time, but no specific near-term financial impact was detailed. Article: Cencora Announces New Organizational and Reporting Structure

Insider Activity

In related news, EVP Elizabeth Campbell sold 11,300 shares of Cencora stock in a transaction on Monday, August 24th. The stock was sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the completion of the sale, the executive vice president directly owned 19,455 shares of the company’s stock, valued at $6,305,754.60. The trade was a 36.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.38% of the stock is owned by corporate insiders.

Cencora Company Profile

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical sourcing and distribution company. It provides branded, generic and specialty pharmaceuticals, over-the-counter products and related health care supplies to pharmacies, hospitals, health systems, physician practices and other health care providers.

The company also offers services to pharmaceutical and biotechnology manufacturers, including logistics, commercialization support, market access, consulting, clinical trial support and patient assistance programs.